Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Mylan N.V. To Contact The Firm Before Lead Plaintiff Deadline
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mylan N.V. (“Mylan” or the “Company”) (NASDAQ:MYL) of the December 12, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Mylan stock or options between February 21, 2012 and October 5, 2016 (the “Class Period”). The case, Perdue v. Mylan N.V. et al, No. 1: 16-cv-08000 was filed on October 13, 2016.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by providing misstatements on payments made to government health-insurance programs with respect to the Company’s EpiPen product.
Specifically, on September 2, 2016, Inside Health Policy published an article revealing that the Centers for Medicare & Medicaid Services (“CMS”) “informed Mylan that it incorrectly classified EpiPen as a generic under the Medicaid rebate program, which caused financial consequences for federal and state governments by reducing the amount of quarterly rebates Mylan owed for its product.”
After the announcement, Mylan’s share price fell from $41.92 per share on September 1, 2016 to a closing price of $39.97 on September 2, 2016—a $1.95 or a 4.65% drop.
A subsequent Bloomberg article published on October 5, 2016, cited a letter from CMS to Senator Ron Wyden of Oregon stating that, due to the misclassification, between 2011 through 2015, Mylan N.V. and Mylan Inc. paid a smaller rebate of 13%, or about $163 million, when it should have been paying a rebate of 23.1% or more.
Then, on October 6, 2016, The Fiscal Times published an article titled “Lawmakers Say EpiPen Maker Bilked Medicare for More than $100 Million”, stating that “[t]he incorrect classification appears to have cost the federal government more than $100 million in the last five years alone.”
After the announcement, Mylan’s share price fell from $38.03 per share on October 5, 2016 to a closing price of $35.94 on October 7, 2016—a $2.09 or a 5.50% drop.
If you invested in Mylan stock or options between February 21, 2012 and October 5, 2016 and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Mylan’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.
* The submission of this form does not create an attorney-client relationship.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.